Safety, immunogenicity, and preliminary efficacy of a randomized clinical trial of omicron XBB.1.5-containing bivalent mRNA vaccine (IMAGE)

Tsinghua University Press

Safety, immunogenicity, and preliminary efficacy of a randomized clinical trial of omicron XBB.1.5-containing bivalent mRNA vaccine

Caption

This is an observer-blinded, three-arms study in 376 patients in Chinese individuals aged from 18 to 55 years old who had previously received three doses COVID-19 vaccine. Immunogenicity in terms of neutralizing antibodies elicited by 30-μg dose of XBB.1.5-containing bivalent vaccine (RQ3027), 30-μg dose of BA.2/BA.5-Alpha/Beta bivalent vaccine (RQ3025) and their precedent 30-μg Alpha/Beta (combined mutations) monovalent mRNA vaccine (RQ3013) and safety are primary and secondary endpoints, respectively. Researchers recorded prescribed COVID-19 cases to explore the preliminary efficacy of three vaccines.

Credit

Zijie Zhang, State Key Laboratory for Conservation and Utilization of Bio-resource and School of Life Sciences, Yunnan University

Usage Restrictions

News organizations may use or redistribute this image, with proper attribution, as part of news coverage of this paper only.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.